Changes in catecholamine level in hypotensive patients subjected to dialysis

Area of Science:

• Nephrology
• Cardiovascular Physiology
• Pharmacology

Background:

• Increased survival in chronic renal failure patients leads to more hypotensive episodes during hemodialysis.
• The relationship between plasma catecholamines and blood pressure fluctuations in dialysis patients is not well understood.

Purpose of the Study:

• To investigate the correlation between plasma catecholamine levels and blood pressure during hemodialysis.
• To explore the potential of amezinium in managing hypotension during hemodialysis.

Main Methods:

• Time-course measurements of plasma catecholamine levels in hemodialysis patients.
• Monitoring blood pressure changes throughout the dialysis session.
• Assessing the effect of amezinium administration on blood pressure and plasma NA levels.

Main Results:

• No significant difference in plasma catecholamine levels was found between pre- and post-hemodialysis.
• A decrease in plasma noradrenalin (NA) levels correlated with a drop in blood pressure 3-4 hours into hemodialysis.
• Amezinium administration helped maintain stable blood pressure during dialysis.

Conclusions:

• Plasma NA concentration is associated with blood pressure reduction during hemodialysis.
• Amezinium may be a viable option for preventing hypotensive episodes in dialysis patients.